Identification of Diabetic Nephropathy in Patients Undergoing Kidney Biopsy through Blood and Urinary Profiles of d-Serine.
biomarker
chiral amino acids
d-serine
diabetes
diabetes and the kidney
diabetic kidney disease
diabetic nephropathy
diagnosis
glomerulonephritis
kidney biopsy
Journal
Kidney360
ISSN: 2641-7650
Titre abrégé: Kidney360
Pays: United States
ID NLM: 101766381
Informations de publication
Date de publication:
25 11 2021
25 11 2021
Historique:
received:
29
06
2021
accepted:
07
09
2021
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
8
4
2022
Statut:
epublish
Résumé
The diagnosis of diabetic nephropathy (DN), the major cause of ESKD, requires kidney biopsy. d-Serine, present only in trace amounts in humans, is a biomarker for kidney diseases and shows potential to distinguish the origin of kidney diseases, whose diagnoses usually require kidney biopsy. We extended this concept and examined the potential of d-serine in the diagnosis of DN. We enrolled patients with biopsy sample-proven DN and primary GN (minimal change disease and IgA nephropathy) and participants without kidney disease. A total of 388 participants were included in this study, and d-serine levels in blood and urine were measured using two-dimensional high-performance liquid chromatography, and urinary fractional excretion (FE) of d-serine was calculated. Using data from 259 participants, we developed prediction models for detecting DN by logistic regression analyses, and the models were validated in 129 participants. A d-serine blood level of >2.34 Analysis of d-serine in blood and urinary excretion is useful in identifying DN in patients undergoing kidney biopsy. Profiling of d-serine in patients with kidney diseases supports the suitable treatment through the auxial diagnosis of the origins of kidney diseases.
Sections du résumé
Background
The diagnosis of diabetic nephropathy (DN), the major cause of ESKD, requires kidney biopsy. d-Serine, present only in trace amounts in humans, is a biomarker for kidney diseases and shows potential to distinguish the origin of kidney diseases, whose diagnoses usually require kidney biopsy. We extended this concept and examined the potential of d-serine in the diagnosis of DN.
Methods
We enrolled patients with biopsy sample-proven DN and primary GN (minimal change disease and IgA nephropathy) and participants without kidney disease. A total of 388 participants were included in this study, and d-serine levels in blood and urine were measured using two-dimensional high-performance liquid chromatography, and urinary fractional excretion (FE) of d-serine was calculated. Using data from 259 participants, we developed prediction models for detecting DN by logistic regression analyses, and the models were validated in 129 participants.
Results
A d-serine blood level of >2.34
Conclusions
Analysis of d-serine in blood and urinary excretion is useful in identifying DN in patients undergoing kidney biopsy. Profiling of d-serine in patients with kidney diseases supports the suitable treatment through the auxial diagnosis of the origins of kidney diseases.
Identifiants
pubmed: 35372995
doi: 10.34067/KID.0004282021
pii: 02200512-202111000-00009
pmc: PMC8785851
doi:
Substances chimiques
Serine
452VLY9402
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1734-1742Informations de copyright
Copyright © 2021 by the American Society of Nephrology.
Déclaration de conflit d'intérêts
A. Hesaka reports having ownership interest in KAGAMI Inc. Y. Isaka reports serving on a speakers bureau for Astellas Pharma Inc., AstraZeneca, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma, and Otsuka Pharmaceutical Co. Ltd.; and receiving research funding from Chugai Pharma Co. Ltd., Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma, and Otsuka Pharmaceutical Co. Ltd. T. Ikeda, M. Mita, and M. Nakane report being cofounders of KAGAMI Inc., a startup company working on chiral amino acids analysis and research for medical application. T. Kimura reports having ownership interest in KAGAMI Inc., and receiving research funding from Kyowa Hakko Kirin Co. Ltd., Shiseido Co. Ltd, and KAGAMI Inc. All remaining authors have nothing to disclose.
Références
Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 63: 1499–1507, 2003 https://doi.org/10.1046/j.1523-1755.2003.00885.x
doi: 10.1046/j.1523-1755.2003.00885.x
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65: 2309–2320, 2004 https://doi.org/10.1111/j.1523-1755.2004.00653.x
doi: 10.1111/j.1523-1755.2004.00653.x
Fiorentino M, Bolignano D, Tesar V, Pisano A, Biesen WV, Tripepi G, D’Arrigo G, Gesualdo L; ERA-EDTA Immunonephrology Working Group: Renal biopsy in patients with diabetes: A pooled meta-analysis of 48 studies. Nephrol Dial Transplant 32: 97–110, 2017 https://doi.org/10.1093/ndt/gfw070
doi: 10.1093/ndt/gfw070
Bermejo S, Garcia-Carro C, Soler MJ: Diabetes and renal disease-should we biopsy? Nephrol Dial Transplant 36: 1384–1386, 2021 https://doi.org/10.1093/ndt/gfz248
doi: 10.1093/ndt/gfz248
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225–232, 2003 https://doi.org/10.1046/j.1523-1755.2003.00712.x
doi: 10.1046/j.1523-1755.2003.00712.x
Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J; ADVANCE Collaborative Group: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20: 1813–1821, 2009 https://doi.org/10.1681/ASN.2008121270
doi: 10.1681/ASN.2008121270
John GT, Date A, Korula A, Jeyaseelan L, Shastry JC, Jacob CK: Nondiabetic renal disease in noninsulin-dependent diabetics in a south Indian Hospital. Nephron 67: 441–443, 1994 https://doi.org/10.1159/000188019
doi: 10.1159/000188019
Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH: Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 316: 602–610, 2016 https://doi.org/10.1001/jama.2016.10924
doi: 10.1001/jama.2016.10924
Kimura T, Hamase K, Miyoshi Y, Yamamoto R, Yasuda K, Mita M, Rakugi H, Hayashi T, Isaka Y: Chiral amino acid metabolomics for novel biomarker screening in the prognosis of chronic kidney disease. Sci Rep 6: 26137, 2016 https://doi.org/10.1038/srep26137
doi: 10.1038/srep26137
Hesaka A, Sakai S, Hamase K, Ikeda T, Matsui R, Mita M, Horio M, Isaka Y, Kimura T: D-Serine reflects kidney function and diseases. Sci Rep 9: 5104, 2019 https://doi.org/10.1038/s41598-019-41608-0
doi: 10.1038/s41598-019-41608-0
Hesaka A, Yasuda K, Sakai S, Yonishi H, Namba-Hamano T, Takahashi A, Mizui M, Hamase K, Matsui R, Mita M, Horio M, Isaka Y, Kimura T: Dynamics of D -serine reflected the recovery course of a patient with rapidly progressive glomerulonephritis. CEN Case Rep 8: 297–300, 2019 https://doi.org/10.1007/s13730-019-00411-6
doi: 10.1007/s13730-019-00411-6
Kimura T, Hesaka A, Isaka Y: D-Amino acids and kidney diseases. Clin Exp Nephrol 24: 404–410, 2020 https://doi.org/10.1007/s10157-020-01862-3
doi: 10.1007/s10157-020-01862-3
Krebs HA: Metabolism of amino-acids: Deamination of amino-acids. Biochem J 29: 1620–1644, 1935 https://doi.org/10.1042/bj0291620
doi: 10.1042/bj0291620
Hashimoto A, Nishikawa T, Hayashi T, Fujii N, Harada K, Oka T, Takahashi K: The presence of free D-serine in rat brain. FEBS Lett 296: 33–36, 1992 https://doi.org/10.1016/0014-5793(92)80397-Y
doi: 10.1016/0014-5793(92)80397-Y
Okushima H, Iwata Y, Hesaka A, Sugimori E, Ikeda T, Nakane M, Mita M, Hayashi T, Isaka Y, Kimura T: Intra-body dynamics of D -serine reflects the origin of kidney diseases. Clin Exp Nephrol 25: 893–901, 2021 https://doi.org/10.1007/s10157-021-02052-5
doi: 10.1007/s10157-021-02052-5
Sugiyama H, Yokoyama H, Sato H, Saito T, Kohda Y, Nishi S, Tsuruya K, Kiyomoto H, Iida H, Sasaki T, Higuchi M, Hattori M, Oka K, Kagami S, Kawamura T, Takeda T, Hataya H, Fukasawa Y, Fukatsu A, Morozumi K, Yoshikawa N, Shimizu A, Kitamura H, Yuzawa Y, Matsuo S, Kiyohara Y, Joh K, Nagata M, Taguchi T, Makino H; Committee for Standardization of Renal Pathological Diagnosis; Committee for Kidney Disease Registry; Japanese Society of Nephrology: Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Clin Exp Nephrol 17: 155–173, 2013 https://doi.org/10.1007/s10157-012-0746-8
doi: 10.1007/s10157-012-0746-8
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators Developing the Japanese Equation for Estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982–992, 2009 https://doi.org/10.1053/j.ajkd.2008.12.034
doi: 10.1053/j.ajkd.2008.12.034
Miyoshi Y, Hamase K, Tojo Y, Mita M, Konno R, Zaitsu K: Determination of D -serine and D -alanine in the tissues and physiological fluids of mice with various D -amino-acid oxidase activities using two-dimensional high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 877: 2506–2512, 2009 https://doi.org/10.1016/j.jchromb.2009.06.028
doi: 10.1016/j.jchromb.2009.06.028
Hamase K, Miyoshi Y, Ueno K, Han H, Hirano J, Morikawa A, Mita M, Kaneko T, Lindner W, Zaitsu K: Simultaneous determination of hydrophilic amino acid enantiomers in mammalian tissues and physiological fluids applying a fully automated micro-two-dimensional high-performance liquid chromatographic concept. J Chromatogr A 1217: 1056–1062, 2010 https://doi.org/10.1016/j.chroma.2009.09.002
doi: 10.1016/j.chroma.2009.09.002
Hamase K, Ikeda T, Ishii C, Ishigo S, Masuyama K, Akita T, Furusho A, Takahashi M, Ide T, Mita M: Determination of trace amounts of chiral amino acids in complicated biological samples using two-dimensional high-performance liquid chromatography with an innovative “shape-fitting” peak identification/quantification method. Chromatography (Basel) 39: 147–152, 2018 https://doi.org/10.15583/jpchrom.2018.019
doi: 10.15583/jpchrom.2018.019
Levin A, Stevens PE: Summary of KDIGO 2012 CKD guideline: Behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 85: 49–61, 2014 https://doi.org/10.1038/ki.2013.444
doi: 10.1038/ki.2013.444
Persson F, Rossing P: Diagnosis of diabetic kidney disease: State of the art and future perspective. Kidney Int Suppl (2011) 8: 2–7, 2018 https://doi.org/10.1016/j.kisu.2017.10.003
doi: 10.1016/j.kisu.2017.10.003
Kimura T, Hesaka A, Isaka Y: Utility of d -serine monitoring in kidney disease. Biochim Biophys Acta Proteins Proteomics 1868: 140449, 2020 https://doi.org/10.1016/j.bbapap.2020.140449
doi: 10.1016/j.bbapap.2020.140449
Miya K, Inoue R, Takata Y, Abe M, Natsume R, Sakimura K, Hongou K, Miyawaki T, Mori H: Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 510: 641–654, 2008 https://doi.org/10.1002/cne.21822
doi: 10.1002/cne.21822
Sasabe J, Miyoshi Y, Rakoff-Nahoum S, Zhang T, Mita M, Davis BM, Hamase K, Waldor MK: Interplay between microbial d -amino acids and host d-amino acid oxidase modifies murine mucosal defence and gut microbiota. Nat Microbiol 1: 16125, 2016 https://doi.org/10.1038/nmicrobiol.2016.125
doi: 10.1038/nmicrobiol.2016.125
Hesaka A, Tsukamoto Y, Nada S, Kawamura M, Ichimaru N, Nakane M, Mita M, Okuzaki D, Okada M, Isaka Y, Kimura T: D-Serine mediates cellular proliferation for kidney remodeling [published online ahead of print August 16, 2021]. Kidney360 https://doi.org/10.34067/KID.0000832021
doi: 10.34067/KID.0000832021
Alicic RZ, Rooney MT, Tuttle KR: Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol 12: 2032–2045, 2017 https://doi.org/10.2215/CJN.11491116
doi: 10.2215/CJN.11491116
Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Tubulointerstitial damage and progression of renal failure. Kidney Int Suppl 68: S82–S86, 2005 https://doi.org/10.1111/j.1523-1755.2005.09915.x
doi: 10.1111/j.1523-1755.2005.09915.x